Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

NeuroPace, Inc. operates as a medical device company in the United States. It develops and sells RNS system, a brain-responsive neuromodulation system for treating medically refractory focal epilepsy by delivering personalized real-time treatment at the seizure source. The company's RNS system also records continuous brain activity data; and enables clinicians to monitor patients in person and remotely. It sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. The company was incorporated in 1997 and is headquartered in Mountain View, California.

NeuroPace, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

MOUNTAIN VIEW, CALIF.--(BUSINESS WIRE)--NEUROPACE, INC. (NASDAQ: NPCE), A MEDICAL DEVICE COMPANY FOCUSED ON TRANSFORMING THE LIVES OF PEOPLE LIVING WITH EPILEPSY, TODAY ANNOUNCED THAT ITS MANAGEMENT TEAM WILL PARTICIPATE IN TWO HEALTHCARE CONFERENCES IN SEPTEMBER. NEUROPACE MANAGEMENT WILL HOST ONE-ON-ONE MEETINGS WITH INVESTORS AT THE WELLS FARGO 2025 HEALTHCARE CONFERENCE, ON WEDNESDAY, SEPTEMBER 3 IN BOSTON, MA. NEUROPACE MANAGEMENT WILL PARTICIPATE IN A FIRESIDE CHAT DISCUSSION AT THE CANTO.

NEUROPACE TO PARTICIPATE IN UPCOMING HEALTHCARE CONFERENCES

-- REPORTED RECORD QUARTERLY REVENUE OF $23.5 MILLION IN Q2 2025-- -- INCREASED FULL-YEAR 2025 REVENUE GUIDANCE TO BETWEEN $94 MILLION AND $98 MILLION AND GROSS MARGIN GUIDANCE TO BETWEEN 75% AND 76%-- -- REMAIN ON TRACK TO SUBMIT NAUTILUS DATA TO FDA FOR POTENTIAL IGE INDICATION EXPANSION IN THE SECOND HALF OF 2025 --CMS MAINTAINS CURRENT MS-DRG ASSIGNMENT FOR RNS SYSTEM PROCEDURES-- MOUNTAIN VIEW, CALIF., AUG. 12, 2025 (GLOBE NEWSWIRE) -- NEUROPACE, INC. (NASDAQ: NPCE), A MEDICAL DEVICE COMPANY FOCUSED ON TRANSFORMING THE LIVES OF PEOPLE LIVING WITH EPILEPSY, TODAY REPORTED FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2025, AND PROVIDED A CORPORATE UPDATE.

NEUROPACE REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND INCREASES 2025 REVENUE GUIDANCE

MOUNTAIN VIEW, CALIF., AUG. 01, 2025 (GLOBE NEWSWIRE) -- NEUROPACE, INC. (NASDAQ: NPCE), A MEDICAL TECHNOLOGY COMPANY FOCUSED ON TRANSFORMING THE LIVES OF PEOPLE LIVING WITH EPILEPSY, TODAY ISSUED THE FOLLOWING STATEMENT IN RESPONSE TO THE CENTERS FOR MEDICARE & MEDICAID SERVICES (CMS) ELECTING NOT TO FINALIZE ITS PROPOSED REASSIGNMENT OF EPILEPSY WITH NEUROSTIMULATOR CASES IN THE FY 2026 INPATIENT PROSPECTIVE PAYMENT SYSTEM (IPPS) RULE.

NEUROPACE COMMENDS CMS FOR MAINTAINING FY25 REIMBURSEMENT STRUCTURE FOR EPILEPSY WITH NEUROSTIMULATOR CASES

NEW YORK , JULY 2, 2025 /PRNEWSWIRE/ -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF NEUROPACE, INC. ("NEUROPACE" OR THE "COMPANY") (NASDAQ: NPCE).SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON AT NEWACTION@POMLAW.COMOR 646-581-9980, EXT.

INVESTOR ALERT: POMERANTZ LAW FIRM INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF NEUROPACE, INC. - NPCE

NEW YORK , JUNE 27, 2025 /PRNEWSWIRE/ -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF NEUROPACE, INC. ("NEUROPACE" OR THE "COMPANY") (NASDAQ: NPCE).SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON AT NEWACTION@POMLAW.COMOR 646-581-9980, EXT.

APPOINTS PATRICK F. WILLIAMS AS CHIEF FINANCIAL OFFICER WILLIAMS BRINGS A TRACK RECORD OF LEADING MEDICAL DEVICE PUBLIC COMPANIES AS CFO REBECCA KUHN DEPARTING COMPANY AND WILL REMAIN IN ADVISORY ROLE MOUNTAIN VIEW, CALIF.

NEUROPACE ANNOUNCES STRATEGIC CFO TRANSITION

NEW YORK, JUNE 23, 2025 (GLOBE NEWSWIRE) -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF NEUROPACE, INC. (NEUROPACE OR THE COMPANY) (NASDAQ: NPCE).SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON AT NEWACTION@POMLAW.COMOR 646-581-9980, EXT.7980.

NEW YORK , JUNE 22, 2025 /PRNEWSWIRE/ -- APOMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF NEUROPACE, INC. ("NEUROPACE" OR THE "COMPANY") (NASDAQ: NPCE).SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON AT NEWACTION@POMLAW.COMOR 646-581-9980, EXT.

NEW YORK CITY, NY / ACCESS NEWSWIRE / JUNE 16, 2025 / POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF NEUROPACE, INC. ("NEUROPACE" OR THE "COMPANY") (NASDAQ:NPCE). SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON AT NEWACTION@POMLAW.COM OR 646-581-9980, EXT.

NEW YORK CITY, NY / ACCESS NEWSWIRE / JUNE 13, 2025 / POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF NEUROPACE, INC. ("NEUROPACE" OR THE "COMPANY") (NASDAQ:NPCE). SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON AT NEWACTION@POMLAW.COM OR 646-581-9980, EXT.

NEW YORK, NY / ACCESS NEWSWIRE / JUNE 12, 2025 / LEVI & KORSINSKY NOTIFIES INVESTORS THAT IT HAS COMMENCED AN INVESTIGATION OF NEUROPACE, INC. ("NEUROPACE, INC.") (NASDAQ:NPCE) CONCERNING POSSIBLE VIOLATIONS OF FEDERAL SECURITIES LAWS. NEUROPACE ISSUED A PRESS RELEASE ON MAY 27, 2025, "ANNOUNC[ING] THE PRELIMINARY PRIMARY ENDPOINT ONE-YEAR RESULTS OF THE TWO-YEAR NAUTILUS STUDY EVALUATING SAFETY AND EFFECTIVENESS OF THE RNS SYSTEM FOR TREATMENT OF INDIVIDUALS WITH DRUG-RESISTANT IDIOPATHIC GENERALIZED EPILEPSY (IGE).

NeuroPace, Inc.

NPCE

Price

Financials Overview

Financial Reports

No items found.

Press Releases

NeuroPace, Inc.

NPCE.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

NPCE